BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193-197. [PMID: 19103636 DOI: 10.1136/ard.2008.095463] [Cited by in Crossref: 149] [Cited by in F6Publishing: 122] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Horimoto AM, da Costa IP. Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity? Rev Bras Reumatol Engl Ed 2016;56:287-98. [PMID: 27476621 DOI: 10.1016/j.rbre.2014.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med 2020;9:E2687. [PMID: 32825112 DOI: 10.3390/jcm9092687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
3 Distler JHW, Györfi A, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 2019;15:705-30. [DOI: 10.1038/s41584-019-0322-7] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 51.5] [Reference Citation Analysis]
4 Cutolo M, Damjanov N, Ruaro B, Zekovic A, Smith V. Imaging of connective tissue diseases: Beyond visceral organ imaging? Best Practice & Research Clinical Rheumatology 2016;30:670-87. [DOI: 10.1016/j.berh.2016.10.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
5 Van Praet JT, Smith V, Haspeslagh M, Degryse N, Elewaut D, De Keyser F. Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study. Arthritis Res Ther 2011;13:R35. [PMID: 21356083 DOI: 10.1186/ar3267] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
6 Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9. [PMID: 22221908 DOI: 10.1016/j.semarthrit.2011.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
7 William BM, Harbert T, Ganti AK, Bierman PJ. Small lymphocytic lymphoma in a patient with CREST syndrome. Hematol Oncol Stem Cell Ther 2011;4:132-5. [PMID: 21982887 DOI: 10.5144/1658-3876.2011.132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
8 Sulli A, Paolino S, Pizzorni C, Ferrari G, Pacini G, Pesce G, Carmisciano L, Smith V, Cutolo M. Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. Rheumatology (Oxford) 2020;59:1051-8. [PMID: 31750929 DOI: 10.1093/rheumatology/kez374] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
9 Maurer B, Distler O. Emerging targeted therapies in scleroderma lung and skin fibrosis. Best Pract Res Clin Rheumatol 2011;25:843-58. [PMID: 22265265 DOI: 10.1016/j.berh.2011.11.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, Laffi G, Zignego AL. Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. J Transl Med. 2014;12:21. [PMID: 24456582 DOI: 10.1186/1479-5876-12-21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
11 Daoussis D, Liossis SN. B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther 2013;15:125. [PMID: 24611177 DOI: 10.1186/ar4392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
12 Mendoza FA, Mansoor M, Jimenez SA. Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs 2016;4:31-47. [PMID: 27812432 DOI: 10.1517/21678707.2016.1114454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
13 Vilela VS, Maretti GB, Silva Gama LMD, Costa CHD, Rufino RL, Levy RA. Tratamento da esclerose sistêmica com rituximabe: uma série de 10 casos em centro único. Revista Brasileira de Reumatologia 2016;56:458-63. [DOI: 10.1016/j.rbr.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
14 Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33796953 DOI: 10.1007/s10067-021-05698-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yoo W. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012;32:795-8. [DOI: 10.1007/s00296-009-1347-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
16 Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012;42:281-96. [PMID: 22542279 DOI: 10.1016/j.semarthrit.2012.03.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
17 Daoussis D, Andonopoulos AP. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Rheumatol Int 2011;31:841-2. [PMID: 20376665 DOI: 10.1007/s00296-010-1485-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52-57. [PMID: 23118116 DOI: 10.3899/jrheum.120778] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
19 Del Papa N, Zaccara E. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Pract Res Clin Rheumatol 2015;29:756-69. [PMID: 27107511 DOI: 10.1016/j.berh.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 . Current world literature. Curr Opin Rheumatol 2010;22:704-12. [PMID: 20881793 DOI: 10.1097/BOR.0b013e3283404094] [Reference Citation Analysis]
21 Becker M, Müller-ladner U, Riemekasten G. Implementation von Leitlinien für eine Therapie der systemischen Sklerose (Sklerodermie): Wunsch und Wirklichkeit. Z Rheumatol 2010;69:310-7. [DOI: 10.1007/s00393-009-0523-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625-31. [PMID: 27839742 DOI: 10.1016/j.semarthrit.2016.10.003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 20.4] [Reference Citation Analysis]
23 Fallet B, Walker UA. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Rev Clin Pharmacol 2020;13:1203-18. [PMID: 33008265 DOI: 10.1080/17512433.2020.1832466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Iudici M. What should clinicians know about the use of glucocorticoids in systemic sclerosis? Modern Rheumatology 2017;27:919-23. [DOI: 10.1080/14397595.2016.1270796] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Kreps EO, Carton C, Cutolo M, Cutolo CA, Vanhaecke A, Leroy BP, Smith V. Ocular involvement in systemic sclerosis: A systematic literature review, it's not all scleroderma that meets the eye. Semin Arthritis Rheum 2019;49:119-25. [PMID: 30660382 DOI: 10.1016/j.semarthrit.2018.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
26 Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-878. [PMID: 21091117 DOI: 10.2217/imt.10.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
27 Yasuoka H. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:97-110. [PMID: 26819563 DOI: 10.4137/CCRPM.S23315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
28 Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-30. [PMID: 21545850 DOI: 10.1016/j.autrev.2011.04.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
29 Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol 2018;36:459-74. [PMID: 30047430 DOI: 10.1016/j.clindermatol.2018.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
30 Zulian F. Scleroderma in children. Best Practice & Research Clinical Rheumatology 2017;31:576-95. [DOI: 10.1016/j.berh.2018.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
31 Lanteri A, Sobanski V, Langlois C, Lefèvre G, Hauspie C, Sanges S, Lambert M, Morell-dubois S, Hatron P, Hachulla E, Launay D, Dubucquoi S. Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmunity Reviews 2014;13:974-80. [DOI: 10.1016/j.autrev.2014.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
32 Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev 2011;10:693-701. [PMID: 21575745 DOI: 10.1016/j.autrev.2011.04.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
33 Yanaba K. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. J Dermatol 2016;43:46-55. [PMID: 26782006 DOI: 10.1111/1346-8138.13026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
34 Sanges S, Jendoubi M, Kavian N, Hauspie C, Speca S, Crave JC, Guerrier T, Lefèvre G, Sobanski V, Savina A, Hachulla E, Hatron PY, Labalette M, Batteux F, Dubucquoi S, Launay D. B Cell Homeostasis and Functional Properties Are Altered in an Hypochlorous Acid-Induced Murine Model of Systemic Sclerosis. Front Immunol 2017;8:53. [PMID: 28223983 DOI: 10.3389/fimmu.2017.00053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics 2017;17:823-33. [DOI: 10.1080/14737159.2017.1356722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
36 Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, Sobanski V, Corli J, Hauspie C, Jendoubi M, Yakoub-Agha I, Hatron PY, Hachulla E, Dubucquoi S. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne 2017;38:113-24. [PMID: 27020403 DOI: 10.1016/j.revmed.2016.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
37 Boin F, Wigley FM. Clinical Features and Treatment of Scleroderma. Kelley's Textbook of Rheumatology. Elsevier; 2013. pp. 1366-1403.e4. [DOI: 10.1016/b978-1-4377-1738-9.00084-0] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
38 Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK. Rituximab in early systemic sclerosis. RMD Open 2017;3:e000384. [PMID: 28879049 DOI: 10.1136/rmdopen-2016-000384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
39 Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med 2014;92:913-24. [DOI: 10.1007/s00109-014-1190-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
40 Becker MO. [Systemic sclerosis : What is currently available for treatment?]. Internist (Berl) 2016;57:1155-63. [PMID: 27796473 DOI: 10.1007/s00108-016-0148-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
41 van Laar JM, Simms RW. Immunomodulatory, Immunoablative, and Biologic Therapies. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 567-82. [DOI: 10.1007/978-3-319-31407-5_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, Sica G, Ferraccioli G. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54. [PMID: 20338043 DOI: 10.1186/ar2965] [Cited by in Crossref: 122] [Cited by in F6Publishing: 101] [Article Influence: 11.1] [Reference Citation Analysis]
43 Lambova S, Müller-ladner U. Systemic Sclerosis. Genomic and Personalized Medicine. Elsevier; 2013. pp. 955-69. [DOI: 10.1016/b978-0-12-382227-7.00079-3] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Nakamura K, Yoshizaki A, Takahashi T, Saigusa R, Taniguchi T, Asano Y, Gonoi W, Hinata M, Shinozaki-ushiku A, Sato S. The first case report of fatal acute pulmonary dysfunction in a systemic sclerosis patient treated with rituximab. Scandinavian Journal of Rheumatology 2016;45:249-50. [DOI: 10.3109/03009742.2015.1102963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Mcqueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67. [DOI: 10.1093/rheumatology/keu463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
46 Takakubo Y, Konttinen YT. Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol 2012;2012:941346. [PMID: 22110541 DOI: 10.1155/2012/941346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
47 Daoussis D, Liossis SN. Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. Mediterr J Rheumatol 2019;30:33-7. [PMID: 32185340 DOI: 10.31138/mjr.30.1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Asano Y. Recent advances in the treatment of skin involvement in systemic sclerosis. Inflamm Regen 2017;37:12. [PMID: 29259711 DOI: 10.1186/s41232-017-0047-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol 2021;40:2621-31. [PMID: 33745085 DOI: 10.1007/s10067-021-05665-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194. [PMID: 24442885 DOI: 10.1136/annrheumdis-2013-204522] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 32.3] [Reference Citation Analysis]
51 Ramos-casals M, Fonollosa-pla V, Brito-zerón P, Sisó-almirall A. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol 2010;6:269-78. [DOI: 10.1038/nrrheum.2010.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
52 Aringer M, Denton CP. Systemic sclerosis phase III clinical trials: Hope on the horizon? Journal of Scleroderma and Related Disorders 2018;3:193-200. [DOI: 10.1177/2397198318775353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
53 Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immun Inflamm Dis 2021. [PMID: 34272836 DOI: 10.1002/iid3.475] [Reference Citation Analysis]
54 van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2010;12:112. [PMID: 20441607 DOI: 10.1186/ar2977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
55 Blank RB, Nwawka OK, Yusov AA, Gordon JK. Inflammatory arthritis in systemic sclerosis: What to do? Journal of Scleroderma and Related Disorders 2019;4:3-16. [DOI: 10.1177/2397198318779532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011;38:289-96. [PMID: 21041277 DOI: 10.3899/jrheum.100361] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
57 Showalter K, Gordon JK. Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker. Curr Rheumatol Rep 2020;23:3. [PMID: 33244633 DOI: 10.1007/s11926-020-00970-z] [Reference Citation Analysis]
58 Cutolo M, Soldano S, Smith V. Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol. 2019;15:753-764. [PMID: 31046487 DOI: 10.1080/1744666x.2019.1614915] [Cited by in Crossref: 51] [Cited by in F6Publishing: 21] [Article Influence: 25.5] [Reference Citation Analysis]
59 Lee JJ, Pope JE. Emerging drugs and therapeutics for systemic sclerosis. Expert Opin Emerg Drugs 2016;21:421-30. [PMID: 27813423 DOI: 10.1080/14728214.2016.1257607] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 2019;46:1006-13. [PMID: 31502326 DOI: 10.1111/1346-8138.15079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
61 Jee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs 2019;79:1511-28. [PMID: 31399860 DOI: 10.1007/s40265-019-01178-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
62 Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 2014;53:975-87. [PMID: 24185765 DOI: 10.1093/rheumatology/ket312] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
63 Zulian F, Balzarin M, Birolo C. Recent advances in the management of juvenile systemic sclerosis. Expert Review of Clinical Immunology 2017;13:361-9. [DOI: 10.1080/1744666x.2017.1243467] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
64 Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology 2012;51:1347-56. [DOI: 10.1093/rheumatology/kes041] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
65 Rath E, Zwerina J, Oppl B, Nell-duxneuner V. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015;165:28-35. [DOI: 10.1007/s10354-014-0331-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
66 Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol 2013;4:266. [PMID: 24046769 DOI: 10.3389/fimmu.2013.00266] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
67 Melissaropoulos K, Liossis SN. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int 2018;38:1225-34. [PMID: 29869007 DOI: 10.1007/s00296-018-4076-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
68 Whitfield ML. Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cell-Depleting Therapies in Autoimmune Diseases in the Genomic Era: Editorial. Arthritis & Rheumatology 2014;66:10-4. [DOI: 10.1002/art.38192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 Eldoma M, Pope J. The contemporary management of systemic sclerosis. Expert Rev Clin Immunol 2018;14:573-82. [PMID: 29874475 DOI: 10.1080/1744666X.2018.1485490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Khor CG, Chen XL, Lin TS, Lu CH, Hsieh SC. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol 2014;33:1019-20. [PMID: 24722688 DOI: 10.1007/s10067-014-2579-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
71 Klavdianou K, Liossis SN, Sakkas L, Daoussis D. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 2017;46:430-8. [PMID: 27670695 DOI: 10.1016/j.semarthrit.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
72 Terao C, Ohmura K, Kawaguchi Y, Nishimoto T, Kawasaki A, Takehara K, Furukawa H, Kochi Y, Ota Y, Ikari K, Sato S, Tohma S, Yamada R, Yamamoto K, Kubo M, Yamanaka H, Kuwana M, Tsuchiya N, Matsuda F, Mimori T. PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis Rheum 2013;65:472-80. [PMID: 23124809 DOI: 10.1002/art.37777] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
73 Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 2019;39:1961-70. [PMID: 31254002 DOI: 10.1007/s00296-019-04357-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
74 Bonroy C, Smith V, Deschepper E, De Keyser F, Devreese K. Specific Antinuclear Antibody Level Changes after B Cell Depletion Therapy in Systemic Sclerosis Are Associated with Improvement of Skin Thickening. J Rheumatol 2016;43:247-9. [DOI: 10.3899/jrheum.150105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
75 Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol 2021;95:107524. [PMID: 33721757 DOI: 10.1016/j.intimp.2021.107524] [Reference Citation Analysis]
76 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
77 De Luca G, Tomelleri A, Dagna L, Matucci-Cerinic M. The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. Clin Rheumatol 2021;40:2529-33. [PMID: 34021841 DOI: 10.1007/s10067-021-05733-4] [Reference Citation Analysis]
78 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017;11:2891-904. [PMID: 29042750 DOI: 10.2147/DDDT.S139248] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
79 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
80 Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271-280. [PMID: 19447770 DOI: 10.1093/rheumatology/kep093] [Cited by in Crossref: 246] [Cited by in F6Publishing: 206] [Article Influence: 20.5] [Reference Citation Analysis]
81 Haroon M, McLaughlin P, Henry M, Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011;5:299-304. [PMID: 21593063 DOI: 10.1177/1753465811407786] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
82 Borrirukwisitsak S, Tantayakom P, Katchamart W. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis. Clin Rheumatol 2021;40:2779-89. [PMID: 33428098 DOI: 10.1007/s10067-020-05542-1] [Reference Citation Analysis]
83 Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews 2018;17:582-7. [DOI: 10.1016/j.autrev.2017.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
84 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 34.5] [Reference Citation Analysis]
85 Sulli A, Ruaro B, Smith V, Paolino S, Pizzorni C, Pesce G, Cutolo M. Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis. Arthritis Res Ther 2017;19:61. [PMID: 28320447 DOI: 10.1186/s13075-017-1270-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
86 Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol. 2011;2011:214013. [PMID: 21826145 DOI: 10.1155/2011/214013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
87 Volkmann ER, Furst DE. Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. Rheum Dis Clin North Am 2015;41:399-417. [PMID: 26210126 DOI: 10.1016/j.rdc.2015.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
88 Smith V, Pizzorni C, Riccieri V, Decuman S, Brusselle G, De Pauw M, Deschepper E, Piette Y, Ruaro B, Sulli A, Vandecasteele E, Melsens K, De Keyser F, Cutolo M. Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study. J Rheumatol 2016;43:995-6. [DOI: 10.3899/jrheum.151018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
89 Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 2013;33:1-18. [PMID: 23011088 DOI: 10.1007/s00296-012-2486-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
90 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
91 Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56. [PMID: 21245206 DOI: 10.1124/pr.109.002006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
92 Asano Y, Varga J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin Cell Dev Biol 2020;101:146-60. [PMID: 31859147 DOI: 10.1016/j.semcdb.2019.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
93 Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmunity Reviews 2015;14:1072-8. [DOI: 10.1016/j.autrev.2015.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
94 Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73. [PMID: 22318389 DOI: 10.1038/jid.2011.472] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
95 Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80. [PMID: 22450392 DOI: 10.1097/BOR.0b013e3283524b9a] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
96 Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA. Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. Arthritis Rheumatol 2018;70:450-61. [PMID: 29193892 DOI: 10.1002/art.40390] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
97 Vilela VS, Maretti GB, Gama LMDS, Costa CHD, Rufino RL, Levy RA. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Revista Brasileira de Reumatologia (English Edition) 2016;56:458-63. [DOI: 10.1016/j.rbre.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
98 Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther. 2012;14:R145. [PMID: 22697462 DOI: 10.1186/ar3879] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
99 Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016;18:131. [PMID: 27267753 DOI: 10.1186/s13075-016-1021-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
100 Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82. [PMID: 29307688 DOI: 10.1016/j.imlet.2018.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
101 Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther 2018;20:75. [PMID: 29669578 DOI: 10.1186/s13075-018-1569-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
102 Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal 2010;4:201-2. [PMID: 21234128 DOI: 10.1007/s12079-010-0107-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, De Langhe E, De Pauw M, Debusschere C, Decuman S, Deroo L, Houssiau F, Lenaerts J, Piette Y, Thevissen K, Vanthuyne M, Westhovens R, Wijnant S, De Keyser F, Smith V. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica 2018;73:119-25. [DOI: 10.1080/17843286.2017.1372244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
104 Sierra-Sepúlveda A, Esquinca-González A, Benavides-Suárez SA, Sordo-Lima DE, Caballero-Islas AE, Cabral-Castañeda AR, Rodríguez-Reyna TS. Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast. Biomed Res Int 2019;2019:4569826. [PMID: 30809542 DOI: 10.1155/2019/4569826] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
105 Rossi D, Sciascia S, Cecchi I, Saracco M, Montabone E, Modena V, Pellerito R, Carignola R, Roccatello D. A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. J Clin Med 2021;10:E292. [PMID: 33466837 DOI: 10.3390/jcm10020292] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Dumoitier N, Chaigne B, Régent A, Lofek S, Mhibik M, Dorfmüller P, Terrier B, London J, Bérezné A, Tamas N, Varin‐blank N, Mouthon L. Scleroderma Peripheral B Lymphocytes Secrete Interleukin‐6 and Transforming Growth Factor β and Activate Fibroblasts. Arthritis & Rheumatology 2017;69:1078-89. [DOI: 10.1002/art.40016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
107 Brady SM, Shapiro L, Mousa SA. Current and future direction in the management of scleroderma. Arch Dermatol Res 2016;308:461-71. [PMID: 27139430 DOI: 10.1007/s00403-016-1647-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
108 Antic M, Distler JH, Distler O. Treating skin and lung fibrosis in systemic sclerosis: a future filled with promise? Curr Opin Pharmacol 2013;13:455-62. [PMID: 23747024 DOI: 10.1016/j.coph.2013.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
109 Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2019;74:272-9. [PMID: 30253707 DOI: 10.1080/17843286.2018.1521904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
110 Matsuda KM, Yoshizaki A, Kuzumi A, Fukasawa T, Ebata S, Miura S, Toyama T, Yoshizaki A, Sumida H, Asano Y, Oba K, Sato S. Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Res Ther 2019;21:129. [PMID: 31138286 DOI: 10.1186/s13075-019-1919-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
111 Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol 2010;19:393-400. [PMID: 20507361 DOI: 10.1111/j.1600-0625.2010.01082.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
112 Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T, Toyama T, Ichimura Y, Noda S, Akamata K, Miyazaki M, Kuwano Y, Yanaba K, Sato S. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014;41:418-20. [PMID: 24801917 DOI: 10.1111/1346-8138.12461] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
113 Horimoto AMC, Costa IPD. Sobreposição de esclerose sistêmica e artrite reumatoide: uma entidade clínica distinta? Revista Brasileira de Reumatologia 2016;56:287-98. [DOI: 10.1016/j.rbr.2014.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
114 Leask A. Emerging targets for the treatment of scleroderma. Expert Opinion on Emerging Drugs 2012;17:173-9. [DOI: 10.1517/14728214.2012.678833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
115 Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010;6:578-87. [PMID: 20703220 DOI: 10.1038/nrrheum.2010.104] [Cited by in Crossref: 152] [Cited by in F6Publishing: 116] [Article Influence: 13.8] [Reference Citation Analysis]
116 Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [PMID: 26497107 DOI: 10.1016/j.autrev.2015.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
117 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
118 Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 2018;45:633-91. [PMID: 29687465 DOI: 10.1111/1346-8138.14162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
119 Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Current Opinion in Rheumatology 2010;22:264-72. [DOI: 10.1097/bor.0b013e328337c3d6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
120 Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015;44:428-36. [PMID: 25300701 DOI: 10.1016/j.semarthrit.2014.09.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 13.1] [Reference Citation Analysis]
121 Kubo S, Smith V, Cutolo M, Tanaka Y. The role of nailfold videocapillaroscopy in patients with systemic sclerosis. Immunol Med 2018;41:113-9. [PMID: 30938276 DOI: 10.1080/25785826.2018.1531189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
122 Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011;17:362-7. [PMID: 21597375 DOI: 10.1097/MCP.0b013e3283483ea5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]